You are here
P&T December 2018
Americans worry more about the cost and availability of health care than any other major societal issue. Clarity in treatment costs could help alleviate stress.
The authors underscore the importance of understanding standards and procedures as they discuss two lawsuits that arose from drug injury.
After being treated with idarucizumab, coagulation parameters in a patient with AKI reverted to normal within 24 hours.
Developing drugs with enhanced safety profiles and improving treatment affordability are vital for patients with MS. The author reviews some encouraging new agents in late-stage development.
New sleep deprivation studies confirm the relationship between inadequate sleep and a wide range of disorders, such as hypertension, obesity and type-2 diabetes, cardiovascular disease, impaired immune functioning, and more.
Treating patients with HCV provides many opportunities for medication errors to occur. These may involve regimen selection, adherence, dispensing, and drug–drug interactions. The authors offer ten safety recommendations.
Leftover or improperly discarded drugs are easy prey for diversion and are fueling the opioid abuse epidemic. ISMP offers safe practice recommendations to prevent drug misuse.
As the door opens to more step therapy and indication-based formularies, P&T committees must walk a fine line between managing treatment costs and providing access to critical drugs.
Approvals, new indications, regulatory activities, and more
Mulpleta (lusutrombopag) for thrombocytopenia; ajovy (fremenezumab-vfrm) for migraine; takhzyro (lanadelumab-flyo) for hereditary angioedema attacks
Steglatro (ertugliflozin) for glycemic control in adults with type-2 diabetes mellitus